Antibody Cocktail Therapy for COVID-19

On October 9, U.S. Eastern Time, Regeneron Pharmaceuticals , which cured President Trump, requested an emergency authorization from federal regulators on Wednesday to distribute the antibody cocktail therapy that the President used during the COVID- 19 treatment last weekend. In the statement, the company emphasized that if the FDA approves it, it will promise to distribute it to Americans free of charge. In the statement, the company emphasized that the current available dose is 50,000, and it hopes to increase to 300,000 available doses in the next few months. The company's REGN-COV2 monoclonal antibody coronavirus therapy was used by President Trump after he was diagnosed with the new corona last week. Although there is no obvious evidence that it has completely improved, Trump himself said that it has been "cured."

In a tweet , Trump said: "We have prepared hundreds of thousands of vaccines. I have prepared an emergency use authorization and we have to sign now. Everyone will get better, and everyone will soon change. Better.” According to a statement issued by White House Press Secretary Kayleigh McEnany on Friday, Trump received 8 grams of REGN-COV2, which allows people outside of clinical trials to obtain experimental drugs. Regeneron Pharmaceuticals said that preclinical studies have shown that REGN-COV2 reduces the number of viruses and related damage to the lungs of non-human primates. The company recently partnered with Roche in Germany, and if approved, it will increase the global supply of REGN-COV2. If the vaccine is finally approved, Regeneron Pharmaceuticals will be responsible for production and distribution in the United States, and Roche will develop, produce and distribute it outside the United States.

According to the official website of Regeneron Pharmaceuticals Inc., which developed this therapy, the therapy named REGN-COV2 is composed of two monoclonal antibodies REGN10933 and REGN10987, which are designed to block the process of new coronavirus infecting the human body. These two antibodies bind to the key receptors of the new coronavirus spike protein in a non-competitive manner. The combination of the two can reduce the ability of mutant viruses to evade single antibody treatment. Regeneron Pharmaceuticals is one of many biotech companies and large pharmaceutical companies that develop vaccines. These companies hope to quickly develop an effective coronavirus treatment method and achieve rapid development. The company began human trials of its antibody cocktail in June, and the third phase of trials began a month later. However, it has not yet been approved by the FDA (U.S. Food and Drug Administration). The FDA can request approval of its management on an individual basis through so-called "compassionate use". Regeneron Pharmaceuticals has made such a request to the FDA to approve Trump's drug management. After President Trump was diagnosed with a new crown infection and used Regeneron, the company's stock price soared by 7% on Monday, bringing its year-to-date increase of more than 60%. After Trump tweeted that he would leave the hospital on Monday night, the stock reached its highest point that day.

In the past 12 months, 26 Wall Street analysts have issued ratings and price targets for Regeneron Pharmaceuticals. The 12-month average target price is $603.58, and the stock is expected to rise by 0.65%. Regeneron Pharmaceuticals has a high target price of US$800.00 and a low target price of US$325.00. Analysts are quite optimistic about this stock. The stock currently has 10 hold ratings, 15 buy ratings and 1 strong buy rating. But there are also many people who call for thinking twice. CNBC commentator Jim Cramer advises investors not to buy shares of Regeneron Pharmaceuticals just because President Trump is cured. Although Trump issued a statement about this antibody drug, there are still only early data available about its potential effectiveness as a treatment. In addition, Trump has also received other treatments for the coronavirus, such as Gilead Sciences ' antiviral drug Remdesivir, so it is difficult to determine the effect of any drug in the absence of randomized clinical trials. Cramer said that this is a key piece of information that investors need to keep in mind when considering whether to buy Regeneron Pharmaceuticals shares, although he believes that "Regeneron Pharmaceuticals is a great company."